Hepatoblastoma is a rare malignant tumor that arises in the liver of infants and young children. It is the most common primary liver cancer in childhood but remains uncommon overall. Most cases are diagnosed in children under three years of age. Awareness of its clinical signs and modern treatments has improved outcomes compared with historical experience.

Clinical features and diagnosis

Children typically present with an enlarging abdominal mass, abdominal pain, or a firm right upper quadrant fullness. Serum alpha-fetoprotein (AFP) is often elevated and is a useful marker for diagnosis and monitoring response to therapy. Imaging studies such as ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) define the size, location and vascular relationships of the tumor and guide surgical planning. Definitive diagnosis generally requires histologic confirmation by biopsy or examination of the resected specimen.

Pathology and subtypes

Hepatoblastoma displays a range of microscopic patterns. Common categories include fetal, embryonal and mixed epithelial types; some tumors show mesenchymal elements or small cell undifferentiated components. Histologic subtype and tumor biology influence treatment decisions and prognosis.

Staging and assessment

  • Imaging determines tumor extent within the liver and involvement of blood vessels and adjacent organs.
  • Staging systems such as PRETEXT are used by multidisciplinary teams to plan therapy and predict resectability.
  • AFP trends, imaging, and pathology together guide risk stratification.

Treatment

Management is multidisciplinary. Surgical removal of the entire tumor offers the best chance of cure when feasible. In many cases, preoperative or postoperative systemic therapy is used to shrink tumors and treat microscopic disease. Therapies commonly include combinations of agents given as chemotherapy and careful surgical planning or liver resection. When the tumor cannot be safely removed, or when disease is extensive, liver transplantation may be considered. Local and supportive measures are part of comprehensive care. Early and complete resection is associated with the best outcomes; incomplete removal or metastatic spread worsens prognosis.

Prognosis, follow-up and research

Outcomes have improved with modern chemotherapy regimens and surgical techniques. Long-term follow-up monitors AFP, imaging for recurrence and late effects of treatment. Clinical trials continue to refine drug combinations, timing of surgery and criteria for transplantation. Families are often cared for by pediatric oncology centers experienced with liver tumors.

Associations and notable facts

Hepatoblastoma may be linked to certain genetic or developmental conditions, including Beckwith‑Wiedemann spectrum features and some hereditary syndromes. Premature birth and low birth weight have been reported more often among affected children in observational studies. Because it is a childhood disease, management emphasizes both cure and minimizing long‑term treatment effects.

For general information about the liver see liver resources; for surgical approaches consult surgery overviews and for pharmacologic therapy see the chemotherapy literature.